Managing Excessive Weight Gain in Children <2 Years of Age: Interviews with Primary Care Providers

Leisha M Andersen1, Darcy A Thompson1

  • 1Department of Pediatrics, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.

Insights

Primary care providers (PCPs) show varied approaches to identifying and discussing early excessive weight gain in children under two. Standardized guidelines and resources are needed to improve management and prevent childhood obesity.

Area of Science:

  • Pediatrics
  • Public Health
  • Childhood Obesity Research

Background:

  • Excessive weight gain in early childhood is a significant risk factor for developing obesity later in life.
  • The lack of standardized guidelines for identifying and treating early excessive weight gain in children under two years old presents challenges for primary care providers (PCPs).

Purpose of the Study:

  • To explore PCPs' perspectives on evaluating and communicating about early excessive weight gain in children under two.
  • To identify barriers perceived by PCPs in managing children with early excessive weight gain.

Main Methods:

  • Conducted 20 semistructured interviews with PCPs regarding their methods for identifying and communicating about early excessive weight gain in children under two.
  • Utilized thematic analysis to interpret interview transcripts.

Main Results:

  • Identified high variability in how PCPs identify excessive weight gain in children under two, despite consistent weight assessment methods.
  • Revealed that PCPs encounter multiple barriers when discussing weight with caregivers, even with existing communication strategies.
  • Highlighted PCPs' perceived need for enhanced support and resources to effectively manage early excessive weight gain.

Conclusions:

  • Significant variability exists among PCPs in identifying, communicating, and responding to early excessive weight gain in young children.
  • Standardized guidelines and resources could improve PCP strategies for managing accelerated weight gain trajectories.
  • Implementing standardized approaches may help mitigate childhood obesity rates by addressing early weight gain effectively.

Related Concept Videos

Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
162
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
172
Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.1K
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
167
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
115
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
174